162 related articles for article (PubMed ID: 18071928)
1. Clinical significance of serum MMP-2 and MMP-7 in patients with ovarian cancer.
Acar A; Onan A; Coskun U; Uner A; Bagriacik U; Atalay F; Unsal DK; Guner H
Med Oncol; 2008; 25(3):279-83. PubMed ID: 18071928
[TBL] [Abstract][Full Text] [Related]
2. Clinical value of combined detection of serum matrix metalloproteinase-9, heparanase, and cathepsin for determining ovarian cancer invasion and metastasis.
Zhang W; Yang HC; Wang Q; Yang ZJ; Chen H; Wang SM; Pan ZM; Tang BJ; Li QQ; Li L
Anticancer Res; 2011 Oct; 31(10):3423-8. PubMed ID: 21965756
[TBL] [Abstract][Full Text] [Related]
3. Clinical Significance of Matrix Metalloproteinases in Blood Plasma of Patients with Gastric Cancer.
Kushlinskii NE; Gershtein ES; Ivannikov AA; Davydov MM; Chang VL; Ognerubov NA; Stilidi IS
Bull Exp Biol Med; 2019 Jan; 166(3):373-376. PubMed ID: 30627896
[TBL] [Abstract][Full Text] [Related]
4. [Expression of matrix metalloproteinases-9,2,7,and tissue inhibitor of metalloproteinases-1,2,3 mRNA in ovarian tumors and their clinical significance].
Hu XX; Li L; Li DR; Zhang W; Cheng XQ; Zhang JQ; Tang BJ
Ai Zheng; 2004 Oct; 23(10):1194-8. PubMed ID: 15473934
[TBL] [Abstract][Full Text] [Related]
5. Matrix metalloproteinases 2, 7, and 9 and tissue inhibitor of metalloproteinases-1 in tumors and serum of patients with ovarian neoplasms.
Gershtein ES; Levkina NV; Digayeva MA; Laktionov KP; Tereshkina IV; Kushlinsky NE
Bull Exp Biol Med; 2010 Oct; 149(5):628-31. PubMed ID: 21165404
[TBL] [Abstract][Full Text] [Related]
6. Matrix metalloproteinase-9 expression correlates with prognosis and involved in ovarian cancer cell invasion.
Hu X; Li D; Zhang W; Zhou J; Tang B; Li L
Arch Gynecol Obstet; 2012 Dec; 286(6):1537-43. PubMed ID: 22832979
[TBL] [Abstract][Full Text] [Related]
7. Expression levels of vascular endothelial growth factor, matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 and 2 in the plasma of patients with ovarian carcinoma.
Manenti L; Paganoni P; Floriani I; Landoni F; Torri V; Buda A; Taraboletti G; Labianca R; Belotti D; Giavazzi R
Eur J Cancer; 2003 Sep; 39(13):1948-56. PubMed ID: 12932675
[TBL] [Abstract][Full Text] [Related]
8. Preoperative angiopoietin-2 serum levels: a marker of malignant potential in ovarian neoplasms and poor prognosis in epithelial ovarian cancer.
Sallinen H; Heikura T; Laidinen S; Kosma VM; Heinonen S; Ylä-Herttuala S; Anttila M
Int J Gynecol Cancer; 2010 Dec; 20(9):1498-505. PubMed ID: 21119365
[TBL] [Abstract][Full Text] [Related]
9. Clinical utility of circulating matrix metalloproteinase-7 (MMP-7), CC chemokine ligand 18 (CCL18) and CC chemokine ligand 11 (CCL11) as markers for diagnosis of epithelial ovarian cancer.
Zohny SF; Fayed ST
Med Oncol; 2010 Dec; 27(4):1246-53. PubMed ID: 19937162
[TBL] [Abstract][Full Text] [Related]
10. The Behavior of MMP-2, MMP-7, MMP-9, and Their Inhibitors TIMP-1 and TIMP-2 in Adenoma-Colorectal Cancer Sequence.
Barabás L; Hritz I; István G; Tulassay Z; Herszényi L
Dig Dis; 2021; 39(3):217-224. PubMed ID: 32961536
[TBL] [Abstract][Full Text] [Related]
11. Matrix metalloproteinase-2 (MMP-2) and -9 (MMP-9) and their tissue inhibitors (TIMP-1 and TIMP-2) in differential diagnosis between low malignant potential (LMP) and malignant ovarian tumours.
Määtta M; Talvensaari-Mattila A; Turpeenniemi-Hujanen T; Santala M
Anticancer Res; 2007; 27(4C):2753-8. PubMed ID: 17695443
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Role of Matrix Metalloproteinases 2, 7, 8, 9 and Their Type 1 Tissue Inhibitor in Blood Serum of Patients with Kidney Cancer.
Kushlinskii NE; Gershtein ES; Alferov AA; Bezhanova SD; Mushtenko VV; Pushkar DY; Matveev VB; Stilidi IS
Bull Exp Biol Med; 2020 Mar; 168(5):673-676. PubMed ID: 32248449
[TBL] [Abstract][Full Text] [Related]
13. Expression of latent matrix metalloproteinase 9 (MMP-9) predicts survival in advanced ovarian cancer.
Lengyel E; Schmalfeldt B; Konik E; Späthe K; Härting K; Fenn A; Berger U; Fridman R; Schmitt M; Prechtel D; Kuhn W
Gynecol Oncol; 2001 Aug; 82(2):291-8. PubMed ID: 11531282
[TBL] [Abstract][Full Text] [Related]
14. Gelatinases and their tissue inhibitors in ovarian tumors; TIMP-1 is a predictive as well as a prognostic factor.
Rauvala M; Puistola U; Turpeenniemi-Hujanen T
Gynecol Oncol; 2005 Dec; 99(3):656-63. PubMed ID: 16112717
[TBL] [Abstract][Full Text] [Related]
15. Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary.
Sakata K; Shigemasa K; Nagai N; Ohama K
Int J Oncol; 2000 Oct; 17(4):673-81. PubMed ID: 10995877
[TBL] [Abstract][Full Text] [Related]
16. Elevated serum matrix metalloproteinase 7 levels predict poor prognosis after radical prostatectomy.
Szarvas T; Becker M; Vom Dorp F; Meschede J; Scherag A; Bánkfalvi A; Reis H; Schmid KW; Romics I; Rübben H; Ergün S
Int J Cancer; 2011 Mar; 128(6):1486-92. PubMed ID: 20473942
[TBL] [Abstract][Full Text] [Related]
17. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.
Ylisirniö S; Höyhtyä M; Turpeenniemi-Hujanen T
Anticancer Res; 2000; 20(2B):1311-6. PubMed ID: 10810441
[TBL] [Abstract][Full Text] [Related]
18. [Study on serum vascular endothelial growth factor level in ovarian malignant tumors].
Li L; Wang LM; Zhang W; Zhang JQ; Song HL; Yao DS; Tang Y; Chen XQ; Yang ZH
Zhonghua Fu Chan Ke Za Zhi; 2003 Feb; 38(2):72-6. PubMed ID: 12783691
[TBL] [Abstract][Full Text] [Related]
19. Matrix metalloproteinases 2, 7, 9 and tissue inhibitor of matrix metalloproteinase-1 in the sera of patients with bone tumors.
Kushlinsky NE; Solovyov YN; Babkina IV; Gershtein ES; Bulicheva IV
Bull Exp Biol Med; 2010 Aug; 149(2):233-5. PubMed ID: 21113498
[TBL] [Abstract][Full Text] [Related]
20. Plasma levels of MMP-7 and TIMP-1 in laboratory diagnostics and differentiation of selected histological types of epithelial ovarian cancers.
Będkowska GE; Gacuta E; Zajkowska M; Głażewska EK; Osada J; Szmitkowski M; Chrostek L; Dąbrowska M; Ławicki S
J Ovarian Res; 2017 Jun; 10(1):39. PubMed ID: 28662671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]